Evidence map›Paper›PMID 30396364›Full record

ArticleTrials2018

New guidance to improve sample size calculations for trials: eliciting the target difference.

Melanie L Bell

Abstract readLetter
In one paragraph

Article in Trials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Colchicine for the primary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Clinical Utility of Advanced Microbiology Testing Tools.Journal of clinical microbiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Melanie L BellDepartment of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, 85724, USA. melaniebell@email.arizona.edu.ORCID http://orcid.org/0000-0003-4821-4094

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
Medical Research Council MC_PC_16101NCI NIH HHS P30 CA023074
6 · The paper itself

Abstract

backgroundSample size calculations are central to the design of health research trials. To ensure that the trial provides good evidence to answer the trial's research question, the target effect size (difference in means or proportions, odds ratio, relative risk or hazard ratio between trial arms) must be specified under the conventional approach to determining the sample size. However, until now, there has not been comprehensive guidance on how to specify this effect. MAIN TEXT: This is a commentary on a collection of papers from two important projects, DELTA (Difference ELicitation in TriAls) and DELTA

conclusionsThe DELTA researchers have developed a set of comprehensive guidance documents that are welcome and will almost certainly improve the way that trials are designed and reported.

Indexed as

Randomized Controlled Trials as TopicSample SizeGuidelines as TopicHumansReproducibility of ResultsEffect sizePowerRandomized controlled trialsSample sizeTarget difference

Identifiers

PMID30396364
PMCPMC6219024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.